Navegando por Palavras-chave "proliferating cell nuclear antigen"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Analysis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma
    (Associação Brasileira de Divulgação Científica, 1999-03-01) Leite, Kátia Ramos Moreira [UNIFESP]; Srougi, Miguel [UNIFESP]; Nesrallah, Luciano João [UNIFESP]; Camara-Lopes, Luiz H [UNIFESP]; Hospital Sírio Libanês; Universidade Federal de São Paulo (UNIFESP)
    The surgical specimens from 51 men submitted to radical prostatectomy for localized prostate cancer were examined by immunohistochemistry using proliferation cell nuclear antigen (PCNA) monoclonal antibody to evaluate the proliferative index (PI). The relationship between PI, biological variables and p53 protein expression was evaluated by immunohistochemistry. PI was low in invasive localized prostate carcinoma (mean, 12.4%) and the incidence of PCNA-positive cells was significantly higher in tumors with p53 expression (P = 0.0226). There was no statistical difference in PCNA values when biological parameters such as Gleason score, tumor volume, extraprostatic involvement, seminal vesicle infiltration or lymph node metastasis were considered. We conclude that proliferative activity is usually low in prostate carcinoma but is correlated with p53 immune staining, indicating that p53 is important in cell cycle control in this neoplasm.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Proliferating cell nuclear antigen (PCNA), p53 and MDM2 expression in Hodgkin's disease
    (Associacao Paulista Medicina, 2007-03-01) Pinheiro, Gevina Silva [UNIFESP]; Silva, Maria Regina Regis [UNIFESP]; Rodrigues, Celso Arrais [UNIFESP]; Kerbauy, Jose [UNIFESP]; Oliveira, José Salvador Rodrigues de [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    CONTEXT and OBJECTIVE: Tumor cells in Hodgkin's disease (HD) express cell proliferation markers that are evaluated according to the oncogenes involved or the expression of their proteins. Correlations between the protein expression grade and clinical data are now important for disease prognosis.DESIGN and SETTING: This was a retrospective analysis on proliferating cell nuclear antigen (PCNA), p53 and MDM2 (murine double minute-2) expression using immunohistochemistry, on formalin-fixed, paraffin-embedded tissues from diagnostic biopsies on 51 patients with HID. the study was conducted at the Division of Hematology and Transfusion Medicine, Hospital São Paulo, Universidade Federal de São Paulo.METHODS: Antigen expression was evaluated as the proportions of positive Hodgkin and Reed-Sternberg (HRS) cells and reactive lymphocytes (L), which were compared using Spearman correlation coefficients. the Friedman test was used for comparisons between the markers. the Pearson test was used to investigate associations between marker expression and clinical and laboratory parameters, marrow involvement, complete remission (CR) and overall survival (OS) rates.RESULTS: There was overexpression of antigen proteins in HRS, in relation to L (p < 0.001). in HRS, MDM2 was higher than p53 and PCNA (p < 0.003), while the latter two were equivalent. in L, p53 was lower than MDM2 and PCNA (p < 0.001), while the latter two were equivalent. There was no relationship between protein expression and clinical and laboratory variables or outcome.CONCLUSIONS: PCNA, p53 and MDM2 are tumor markers for HID, but showed no clinical or prognostic significance in our analysis.